Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Equity Ratio (2018 - 2025)

BioNexus Gene Lab's Equity Ratio history spans 8 years, with the latest figure at 0.93 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.93 for Q4 2025, up 16.72% from a year ago — trailing twelve months through Dec 2025 was 0.93 (up 16.72% YoY), and the annual figure for FY2025 was 0.93, up 16.72%.
  • Equity Ratio for Q4 2025 was 0.93 at BioNexus Gene Lab, up from 0.89 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.93 in Q4 2025 to a low of 0.69 in Q1 2021.
  • The 5-year median for Equity Ratio is 0.81 (2023), against an average of 0.8.
  • The sharpest move saw Equity Ratio crashed 89.05% in 2021, then grew 21.04% in 2024.
  • Year by year, Equity Ratio stood at 0.75 in 2021, then grew by 1.69% to 0.76 in 2022, then grew by 11.1% to 0.85 in 2023, then decreased by 5.85% to 0.8 in 2024, then grew by 16.72% to 0.93 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.93, 0.89, and 0.8 for Q4 2025, Q3 2025, and Q2 2025 respectively.